首页> 美国卫生研究院文献>other >Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study
【2h】

Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study

机译:高风险早期乳腺癌患者不同临床治疗评分评估预后的能力比较:希腊合作肿瘤小组研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background-AimEarly breast cancer is a heterogeneous disease, and, therefore, prognostic tools have been developed to evaluate the risk for distant recurrence. In the present study, we sought to develop a risk for recurrence score (RRS) based on mRNA expression of three proliferation markers in high-risk early breast cancer patients and evaluate its ability to predict risk for relapse and death. In addition the Adjuvant! Online score (AOS) was also determined for each patient, providing a 10-year estimate of relapse and mortality risk. We then evaluated whether RRS or AOS might possibly improve the prognostic information of the clinical treatment score (CTS), a model derived from clinicopathological variables.
机译:背景技术早期乳腺癌是一种异质性疾病,因此,已开发出预后工具以评估远处复发的风险。在本研究中,我们试图根据高危早期乳腺癌患者中三种增殖标志物的mRNA表达来制定复发风险评分(RRS),并评估其预测复发和死亡风险的能力。另外佐剂!还确定了每位患者的在线评分(AOS),以提供10年复发和死亡风险的估计。然后,我们评估了RRS或AOS是否可能改善临床治疗评分(CTS)的预后信息,CTS是一种源自临床病理变量的模型。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号